Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (186)	11/11/1998 12:30:00 PM
From: ADEL 7	Read Replies (2) \| Respond to of 1386

I hope that the study will be published in one of the following journals: 1-Annals of Internal Medicine 2-The New England Journal of Medicine ( the best ) 3-Journal of the American Medical Association. Lancet is a great journal but it is published in England and it is known among medical community as an aggressive journal which can do publications for controversial topics which later proved to be inaccurate or accurate. The best exposure Pharmos can get is by publishing the study in the New England. It will be a major event for sure. Will be discussed in many journal clubs in most hospitals in USA. It will also be covered by ABC news and others for sure. Take care Adel